DealsAug 5, 2026, 07:04 AM
Eton Pharma Licenses US Rights to ASN-001 for Infantile Hemangioma
AI Summary
Eton Pharmaceuticals, Inc. has entered into a license agreement with Auson Pharmaceuticals Inc. for the U.S. rights to ASN-001 (timolol topical gel), a late-stage rare disease product candidate for proliferating superficial infantile hemangiomas. Eton will pay an upfront fee of $3.0 million, with potential milestone payments up to $33.5 million based on FDA approval and sales targets, plus tiered royalties. The company plans to submit a New Drug Application (NDA) in the second half of 2027, aiming to address a patient population estimated at 20,000 to 30,000 annually and complement its existing HEMANGEOL product.
Key Highlights
- Eton Pharmaceuticals licensed US rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals.
- Eton will pay an upfront license fee of $3.0 million to Auson.
- NDA submission for ASN-001 is anticipated in the second half of 2027.
- Potential milestone payments include $5.0 million upon first commercial sale after FDA approval.
- Additional milestone payments up to $10.0 million for annual net sales exceeding $280 million.
- Tiered royalties range from 10% for sales up to $200 million to 15% for sales over $400 million.
- ASN-001 targets 20,000 to 30,000 patients annually for moderate infantile hemangiomas.
- Phase II/III trials showed 56% elimination/near-elimination for BID dosing vs. 15% for placebo.
Price Impact
More from ETON